Key Points
- CFO Mark Ragosa sold 42,841 shares on Dec. 8 at an average price of $41.49 for proceeds of about $1.78 million, leaving him with 31,086 shares — a 57.95% reduction in his stake.
- Ragosa also sold 19,900 shares on Nov. 12 and 100 shares on Oct. 28, bringing his recent insider sales to roughly $2.60 million over the past two months.
- Kiniksa recently reported $0.23 EPS (missing the $0.31 estimate) but beat revenue at $180.86 million (+61.2% YoY); the stock trades near $40.54 with a market cap of about $3.07 billion and an average analyst target of $52.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the completion of the sale, the chief financial officer owned 31,086 shares in the company, valued at approximately $1,289,758.14. This trade represents a 57.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Mark Ragosa also recently made the following trade(s):
- On Wednesday, November 12th, Mark Ragosa sold 19,900 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $40.94, for a total transaction of $814,706.00.
- On Tuesday, October 28th, Mark Ragosa sold 100 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.00, for a total transaction of $4,100.00.
Kiniksa Pharmaceuticals International Trading Down 1.5%
Shares of KNSA opened at $40.54 on Thursday. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $42.98. The firm's 50-day moving average price is $39.70 and its 200-day moving average price is $34.29. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of 90.09 and a beta of 0.02.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). The company had revenue of $180.86 million during the quarter, compared to analysts' expectations of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business's quarterly revenue was up 61.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.18) earnings per share. On average, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the company. Citigroup lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Friday, October 17th. Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an "overweight" rating in a report on Thursday, September 25th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 6th. Weiss Ratings reissued a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Finally, Wedbush restated an "outperform" rating and issued a $48.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, December 2nd. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of "Moderate Buy" and an average target price of $52.00.
View Our Latest Stock Analysis on Kiniksa Pharmaceuticals International
Hedge Funds Weigh In On Kiniksa Pharmaceuticals International
Several hedge funds and other institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its position in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Corebridge Financial Inc. grew its holdings in Kiniksa Pharmaceuticals International by 3.6% in the first quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock worth $355,000 after purchasing an additional 549 shares during the last quarter. Martingale Asset Management L P increased its position in Kiniksa Pharmaceuticals International by 1.3% during the 1st quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock valued at $1,111,000 after buying an additional 640 shares in the last quarter. Mariner LLC raised its position in shares of Kiniksa Pharmaceuticals International by 5.8% in the 3rd quarter. Mariner LLC now owns 13,253 shares of the company's stock valued at $515,000 after purchasing an additional 732 shares during the last quarter. Finally, USA Financial Formulas acquired a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth about $32,000. 53.95% of the stock is owned by institutional investors.
Kiniksa Pharmaceuticals International Company Profile
(
Get Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
